Characteristics and outcome of the 15 H pylori–positive patients treated
Patient no. . | Age, y (sex) . | ITP duration, y . | Previous treatment(s) . | Treatment(s) at inclusion and daily dose(s) . | Plt count at inclusion, × 109/L . | H pylori eradication . | Plt count after 3 mos, × 109/L . | Plt count after 6 mos, × 109/L . | Follow-up, mos . | Additional treatment for ITP (time after the PrevPac) . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 50 (F) | 21 | spl, IVIg, dan, aza, mmf | None | 19 | Yes | 21 | 34 | 18 | IVIg (7 d), ritux (3 mos) |
| 2 | 47 (F) | 20 | pred, spl, ritux | None | 18 | Yes | 15 | 14 | 17 | IVIg (repeatedly) |
| 3 | 68 (F) | 20 | pred, anti-D | None | 22 | Yes | 26 | 44 | 18 | anti-D (3 mos) |
| 4 | 66 (F) | 19 | IVIg, pred | None | 21 | Yes* | 15 | 32 | 18 | IVIg (repeatedly) |
| 5 | 23 (M) | 20 | IVIg, anti-D | None | 43 | Yes | 59 | 9 | 14 | anti-D (6 mos) |
| 6 | 71 (F) | 6 | IVIg, dan | dan 400 mg | 43 | Yes | 25 | 35 | 13 | IVIg (3 mos), ritux (5 mos) |
| 7 | 27 (F) | 1 | IVIg, pred | pred 5 mg | 34 | Yes | 42 | 10 | 10 | IVIg (6 mos) |
| 8 | 69 (M) | 5 | IVIg, pred, spl, anti-D, dan, ritux | None | 10 | Yes | 15 | 19 | 8 | No further treatment needed (no bleeding symptoms) |
| 9 | 37 (M) | 10 | pred, anti-D, IVIg | None | 54 | Yes | 44 | ND | 3 | No further treatment needed |
| 10 | 43 (M) | 12 | pred, IVIg, dan | pred 30 mg | 20 | Yes | 45 | 400 | 12 | spl (3.5 mos) (CR) |
| 11 | 56 (F) | 2 | pred, anti-D, IVIg | None | 53 | Yes | 25 | 55 | 11 | anti-D (5 mos) |
| 12 | 61 (F) | 5 | pred, IVIg, aza, dan, spl, anti-CD40L | aza 100 mg | 37 | Yes | 78 | 100 | 7 | dan (7 mos) |
| 13 | 47 (F) | 4 | pred, IVIg, dan, vcr, aza, anti-D | dan 200 mg, aza 200 mg | 45 | Yes* | 54 | 105 | 11 | IVIg (7 d), mmf and cycl (2 mos) (associated AIHA) |
| 14 | 74 (F) | 5 | pred, IVIg, anti-D | vit C 1000 mg | 54 | No† | 58 | 88 | 6 | No further treatment needed |
| 15 | 56 (F) | 18 | pred, IVIg, mmf, spl | pred 5 mg, mmf 2000 mg | 25 | Yes | 6 | ND | 3 | IVIg (21 d and then repeated every 3 wks) |
Patient no. . | Age, y (sex) . | ITP duration, y . | Previous treatment(s) . | Treatment(s) at inclusion and daily dose(s) . | Plt count at inclusion, × 109/L . | H pylori eradication . | Plt count after 3 mos, × 109/L . | Plt count after 6 mos, × 109/L . | Follow-up, mos . | Additional treatment for ITP (time after the PrevPac) . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 50 (F) | 21 | spl, IVIg, dan, aza, mmf | None | 19 | Yes | 21 | 34 | 18 | IVIg (7 d), ritux (3 mos) |
| 2 | 47 (F) | 20 | pred, spl, ritux | None | 18 | Yes | 15 | 14 | 17 | IVIg (repeatedly) |
| 3 | 68 (F) | 20 | pred, anti-D | None | 22 | Yes | 26 | 44 | 18 | anti-D (3 mos) |
| 4 | 66 (F) | 19 | IVIg, pred | None | 21 | Yes* | 15 | 32 | 18 | IVIg (repeatedly) |
| 5 | 23 (M) | 20 | IVIg, anti-D | None | 43 | Yes | 59 | 9 | 14 | anti-D (6 mos) |
| 6 | 71 (F) | 6 | IVIg, dan | dan 400 mg | 43 | Yes | 25 | 35 | 13 | IVIg (3 mos), ritux (5 mos) |
| 7 | 27 (F) | 1 | IVIg, pred | pred 5 mg | 34 | Yes | 42 | 10 | 10 | IVIg (6 mos) |
| 8 | 69 (M) | 5 | IVIg, pred, spl, anti-D, dan, ritux | None | 10 | Yes | 15 | 19 | 8 | No further treatment needed (no bleeding symptoms) |
| 9 | 37 (M) | 10 | pred, anti-D, IVIg | None | 54 | Yes | 44 | ND | 3 | No further treatment needed |
| 10 | 43 (M) | 12 | pred, IVIg, dan | pred 30 mg | 20 | Yes | 45 | 400 | 12 | spl (3.5 mos) (CR) |
| 11 | 56 (F) | 2 | pred, anti-D, IVIg | None | 53 | Yes | 25 | 55 | 11 | anti-D (5 mos) |
| 12 | 61 (F) | 5 | pred, IVIg, aza, dan, spl, anti-CD40L | aza 100 mg | 37 | Yes | 78 | 100 | 7 | dan (7 mos) |
| 13 | 47 (F) | 4 | pred, IVIg, dan, vcr, aza, anti-D | dan 200 mg, aza 200 mg | 45 | Yes* | 54 | 105 | 11 | IVIg (7 d), mmf and cycl (2 mos) (associated AIHA) |
| 14 | 74 (F) | 5 | pred, IVIg, anti-D | vit C 1000 mg | 54 | No† | 58 | 88 | 6 | No further treatment needed |
| 15 | 56 (F) | 18 | pred, IVIg, mmf, spl | pred 5 mg, mmf 2000 mg | 25 | Yes | 6 | ND | 3 | IVIg (21 d and then repeated every 3 wks) |
Plt indicates platelet; mos, months; y, years; spl, splenectomy; IVIg, intravenous immunoglobulin; dan, danazol; aza, azathioprine; mmf, mycophenolate mofetil; d, day; ritux, rituximab; pred, prednisone; anti-D, intravenous anti-D; ND, not done; anti-CD40L, anti-CD40 ligand monoclonal antibody; vcr, vincristine; AIHA, autoimmune hemolytic anemia; vit C, vitamin C; wks, weeks; and CR, complete response.
Required an alternative eradication regimen (allergy or failed to be eradicated after the Prevpac).
Alternative regimen had to be stopped after a week because of side-effects (diarrhea and vomiting). Patient no. 10 did not respond after 5 months and subsequently underwent a splenectomy and achieved a complete response after the procedure. After 7 months of follow-up, patient no. 12 relapsed (platelet count = 53 × 109/L).